TPOR complex structure-driven analogs of TPO
Ontology highlight
ABSTRACT:
PROVIDER: PRJEB61988 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| ERR11421546_1.fastq.gz | Fastqsanger.gz | |||
| ERR11421546_2.fastq.gz | Fastqsanger.gz | |||
| ERR11421547_1.fastq.gz | Fastqsanger.gz | |||
| ERR11421547_2.fastq.gz | Fastqsanger.gz | |||
| ERR11421562_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 8 |
Similar Datasets
Project description:The purpose of this study was to characterize the gene expression profile of MDA-MB-231 breast cancer cells treated with various SCFA-hexosamine analogs to better understand the role of various modifications to this scaffold. Experiment Overall Design: In total, six analogs were investigated in this study. For the relatively ""toxic"" C6-SCFA analogs, IC30 was selected to explore initial growth inhibitory and apoptotic gene expression changes. Two independent biological replicates were analyzed for each analog-treated condition. Three independent biological replicates were analyzed for the vehicle-treated control (EtOH).
2009-05-17 | E-GEOD-11407 | biostudies-arrayexpress
Project description:This dataset was acquired to identify human proteins binding to tetraphosphate mRNA cap analogs. Affinity resins were derivatized with tetraphosphate mRNA cap analogs or a trinucleotide cap control and affinity purification performed in HEK293F cell extracts. The pulled-down proteins were eluted using soluble cap analogs, subjected to digestion with trypsin, TMT labelling, and nLC-MS/MS analysis.
2024-10-02 | PXD053198 | Pride
Project description:Detection of Base Analogs Incorporated During DNA Replication by Nanopore Sequencing
| PRJEB31378 | ENA
Project description:Analogs of ManNAc, the committed precursor of sialic acid, decrease metastatic potential and trigger apoptosis in cancer cells. Adding Lev to ManNAc analogs increases their toxicity due to an ill-understood mechanism. Comparing gene expression profiles of cells treated with Ac4ManNLev and Ac4ManNAc will provide insight into the similarities and differences of these analogs. Specifically, MDA-MB-231 human breast cancer cells will be treated with Ac4ManNLev and Ac4ManNAc at doses that inhibit cell growth and induce the cell to undergo apoptosis later. RNA will be harvested in the early stage of cell arrest in order to identify genes altered by Ac4ManNLev and Ac4ManNAc.
2011-04-29 | GSE28939 | GEO
Project description:Transcriptional profiling of valproic acid and valproic acid analogs in human embryonic stem cells.
2010-12-31 | E-MEXP-2374 | biostudies-arrayexpress
Project description:Analogs of ManNAc, the committed precursor of sialic acid, decrease metastatic potential and trigger apoptosis in cancer cells. Adding Lev to ManNAc analogs increases their toxicity due to an ill-understood mechanism. Comparing gene expression profiles of cells treated with Ac4ManNLev and Ac4ManNAc will provide insight into the similarities and differences of these analogs. Specifically, MDA-MB-231 human breast cancer cells will be treated with Ac4ManNLev and Ac4ManNAc at doses that inhibit cell growth and induce the cell to undergo apoptosis later. RNA will be harvested in the early stage of cell arrest in order to identify genes altered by Ac4ManNLev and Ac4ManNAc. RNA preparations from three conditions, were sent to Microarray Core (E). One as control (Ethanol), and two experimental groups: high concentration Ac4ManNAc (100 uM) and high concentration Ac4ManNLev (100 uM). The aim is to gain insight into apoptosis and cell cycle arrest. Specifically, the Ac4ManNLev samples will be comprared to a less potent ManNAc analog. The RNA was amplified, labeled, and hybridized to the GLYCOv3 microarrays.
2011-04-29 | E-GEOD-28939 | biostudies-arrayexpress
Project description:The Pseudomonas aeruginosa MvfR-dependent QS regulatory pathway controls the expression of key virulence genes; and is activated via the extracellular signals 4-hydroxy-2-heptylquinoline (HHQ) and 3,4-dihydroxy-2-heptylquinoline (PQS), whose syntheses depend on anthranilic acid (AA), the primary precursor of 4-hydroxy-2-alkylquinolines (HAQs). We identified halogenated AA analogs that specifically inhibited HAQ biosynthesis and disrupted MvfR-dependent gene expression. These compounds restricted P. aeruginosa systemic dissemination and mortality in mice, without perturbing bacterial viability, and inhibited osmoprotection, a widespread bacterial function.
2009-07-17 | GSE17111 | GEO
Project description:The ubiquitous efflux transporter ATP-binding cassette sub-family C member 5 (ABCC5) is present at high levels in the blood-brain barrier, neurons and glia, but its in vivo substrates and function are not known. Untargeted metabolomic screens revealed that Abcc5-/- mice accumulate endogenous glutamate conjugates and analogs in several tissues, but brain in particular. The abundant neurotransmitter N-acetylaspartylglutamate (NAAG), for example, was over 2-fold higher in Abcc5-/- brain. In line with ABCC5-mediated transport, the metabolites that accumulated in Abcc5-/- tissues were depleted in cultured cells that overexpressed human ABCC5. Using membrane vesicles, we show that ABCC5 not only transports the metabolites detected in our screen, but also a wide range of peptides containing a C-terminal glutamate. Glutamate conjugates are of physiological relevance because they can affect the function of glutamate, the principal excitatory neurotransmitter in the brain. We found that ABCC5 also transports exogenous glutamate analogs, like the classic excitotoxic neurotoxins kainic acid, domoic acid and N-methyl-D-aspartate (NMDA) and the therapeutic glutamate analog ZJ43. Taken together, we have identified ABCC5 as a general glutamate conjugate and analog transporter that affects the disposition of endogenous metabolites, toxins and drugs.
2015-10-01 | GSE68628 | GEO
Project description:Tuberculosis (TB) which is one of the deadliest infectious disease worldwide, is caused by the inhalation of the pathogenic bacteria Mycobacterium tuberculosis. Since many years now, the emergence of multiple (MDR), extensively (XDR) and totally (TDR) drug resistant strains amplifies the incidences of TB resulting in failure of treatment and death. However, no new TB drug classes have been developed or approved for drug susceptible TB since the current 6-month four-drug combination was introduced in the 1970s. Most of the promising new molecules in development are either repurposed drug compounds or new derivatives of known anti-mycobacterial drugs that mainly target the bacteria cell wall biosynthesis. It is now acknowledged that microbial lipolytic enzymes are involved in bacterial growth, cell wall biosynthesis, carbon sources management and virulence during infections by M. tuberculosis. Although no drug is reported to target specifically enzymes involved in mycobacterial intracellular lipid metabolism; our results have clearly shown that mycobacterial enzymes can be potential therapeutic targets. Consequently, specific inhibitors of such enzymes might turn out to be valuable anti-tuberculous agents. We previously reported that the Cyclophostin & Cyclipostins (CyC) analogs are a new family of potent antimycobacterial molecules which react specifically and covalently with (Ser/Cys)-based enzymes. Competitive ABPP approach with CyC17-pretreated M. tb lysate and the ActivX Desthiobiotin-FP activity-based probe (ABP) allowed identifying 23 distinct proteins as potential targets of this inhibitor, that were all (Ser/Cys)-based enzymes, most of them participating in M. tb lipid metabolism and cell wall biosynthesis. However, this approach for target identification in cell lysates is mostly indirect with the risk of false positive hits, and cannot be applied in vivo for various technical reasons, the main one being the need for a large number of compounds and cells. To overcome these issues, we report here the synthesis of new CyC alkyne-containing inhibitors (i.e., CyCyne) analogous to CyC17, and their use for the direct fishing of target proteins in living M. tb via bio-orthogonal click-chemistry activity-based protein profiling (CC-ABPP) strategy. In particular, we further explore and validate, through a combination of biochemical and structural approaches, the specificity of inhibition of the HsaD activity by the CyC analogs.
2022-09-20 | PXD034921 | Pride
Project description:Recent clinical studies have suggested that the risk of developing hepatocellular carcinoma might be lower in chronic hepatitis B (CHB) patients receiving tenofovir disoproxil fumarate (TDF) than in patients receiving entecavir (ETV), although there is no difference in biochemical and virological remission between two drugs. The effects of nucleoside analogs (NsAs; lamivudine and ETV) or nucleotide analogs (NtAs; adefovir disoproxil [ADV], TDF, and tenofovir alafenamide [TAF]) on cell growth and the expression of growth signaling molecules were investigated. The tumor inhibitory effects of NsAs or NtAs were evaluated using a mouse xenograft model, and protein phosphorylation profiles were investigated.
2024-01-17 | GSE249861 | GEO